Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  6.00 5.11% 123.50 122.00 125.00 127.00 117.50 117.50 137,962 15:51:42
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.1 -13.9 -35.9 - 70

Reneuron Share Discussion Threads

Showing 7776 to 7798 of 8350 messages
Chat Pages: Latest  322  321  320  319  318  317  316  315  314  313  312  311  Older
DateSubjectAuthorDiscuss
22/1/2020
10:37
Not at the current price I hope.
investordave
22/1/2020
10:24
"#RENE Will foson buy them ?" Https://twitter.com/Trader__007/status/1219927774502227969
tromso1
22/1/2020
10:15
And long may it continue.
investordave
22/1/2020
10:14
Everyone happy to buy today.
small crow
21/1/2020
14:44
Here they come..
investordave
21/1/2020
13:39
We'll probably find that a few silly sellers come out to play soon to cash in their few pence in profit. I'm in this one for the longer term. The potential is huge in my view.
investordave
21/1/2020
13:35
nut not nit
martinfrench
21/1/2020
13:04
Glad I increased my holding yesterday
ayl30
21/1/2020
12:58
rather, just one of the stocks he has prob got right but in the context of things he was awful. even a blind squirrel can find a nit occasionally
martinfrench
21/1/2020
12:58
Sadly "patient" is not a word most people seem to understand these days...
bonzo
21/1/2020
12:47
Neil Woodford knew what he was doing investing in this. His clients didn't. Now they have withdrawn their money and run away, they will be the losers.
icejelly
21/1/2020
12:25
That's more like it.
small crow
17/1/2020
13:44
Thanks for the article, Lauders. It seems to have generated some enthusiasm today, presumably on the thought that it might be acquired. Why no one has stepped up to buy the 33% from Ex-Woodford funds-on the cheap-suggests any acquirers are in Show Me mode. Let's hope that the updates from the RP trials this year give us (and them) good news.
dickbush
17/1/2020
12:49
They just have! Bought a few more.
napoleon 14th
17/1/2020
12:21
Just topped up again, these have to start moving up at some point!
bonzo
17/1/2020
10:27
RENE mentioned in this piece: Https://www.investorschronicle.co.uk/shares/2020/01/16/picking-merger-winners/ Whether it comes to be is another matter completely, but interesting RENE are included. These scenarios could eventually play out for a minnow such as ReNeuron, a £44m gene therapy specialist which we have previously described as having “highly promising technologies tempered by uncertainties linked to the funding imperative”. The company is developing stem-cell technologies for use in therapies to combat chronic stroke disability and certain types of retinal degeneration. Clinical results have been positive, but the company’s management is attempting to shorten the overall time to market approval, thereby easing the capital imperative to a degree. ReNeuron had net cash of £20.3m at the time of its September interim result, but it burnt through £7.48m in net cash during FY2019 with R&D expenditure up 22 per cent to £9.23m. We do not envisage any let-up in the capital demands given the clinical trials in prospect, but matters have been helped by the payment of half of the £12m upfront fee from Fosun Pharma for the potential commercial exploitation of the company’s therapies in China. The agreement with Fosun, signed last April, could generate success-based milestone payments of £80m and double-digit royalties on sales, but it is hard to imagine that a $14.5bn (£11.2bn) group like Fosun wouldn’t be interested in incorporating ReNeuron’s intellectual property within its balance sheet further down the track. Asia is currently the fastest growing region for pharmaceutical investment in the world – with M&A playing an increasingly prominent role. Gene-based therapies represent the new frontier in medical research, underpinning a new tailored approach to clinical applications, aided by the accumulation of massive new datasets across population groups. If ReNeuron’s technologies are eventually deemed efficacious by regulators, then Fosun may have to act quickly, because these technologies would not have gone unnoticed closer to home.
lauders
07/1/2020
11:17
I did wonder about that martinfrench, but I thought only UK and US based patients would be considered. Could be a bit challenging in Thailand. Will certainly watch and perhaps send a message to the company if more and more progress is evident.
lauders
07/1/2020
11:11
depending on his financial situation i would volunteer for trials
martinfrench
06/1/2020
01:45
Yesterday I spent most of the day with one of my wife's friends and her second eldest son (24 years old). They are Thai and I learnt that he has retinitis pigmentosa (RP). It was an eye-opener to hear directly from him about his daily challenges. He doesn't like to go to crowded places as he can bump into people as his tunnel vision doesn't allow him to see around him clearly, he has nearly been hit by two cars trying to cross the road, when people try to shake hands with him they look at him strangely when he doesn't seem to lift his hand and reciprocate etc... These are just some of the obvious things that struck me as frustrating for him and things that we normal folk would not even consider/understand. He seemed to know about Reneuron and I showed him the website on my mobile so he knows there is some hope, but at what price and when? These are the critical things in his mind as his eyesight diminishes. I now have even more reason to see RENE's work pay-off and hope that I will be able to see him benefit from it all, before it is too late for him. Fingers and everything else crossed!
lauders
31/12/2019
10:26
Looking very strong after a strong period of consolidation we should see further commercial deals in short order as per recent interview.
diversification
31/12/2019
10:02
Three cheers for the last day of the year's trading. Break-out above 50 day moving average which is also bottoming out.
dickbush
31/12/2019
09:20
Idp looks lovely as well!My top picks for 2020
costax1654x
26/12/2019
08:33
Very interesting that Michael Schumacher is undergoing stem cell surgery to try and help him. Hope the outcome is very positive for him and his legion of fans. Let 2020 be a great year for him in the way of recovery and hence an easier one for his family. Http://www.msn.com/en-gb/sport/formula1/michael-schumachers-wife-gives-rare-update-about-f1-legend/ar-BBYlgcD?ocid=ientp
lauders
Chat Pages: Latest  322  321  320  319  318  317  316  315  314  313  312  311  Older
ADVFN Advertorial
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210621 04:54:38